Although preclinical or clinical studies remain missing, targeting the MR1-TCR axis with synthetic MR1 ligands is expected to effectively enhance MR1T-mediated cytotoxicity or suppress MR1T cell function when dysregulation contributes to tumor growth. This evidence concerns the gene MR1 and neoplasm.